A Small Molecule Promoting Neural Differentiation Suppresses Cancer Stem Cells in Colorectal Cancer

Cancer stem cells (CSCs) are a tumor cell subpopulation that drives tumor progression and metastasis, leading to a poor overall survival of patients. In colorectal cancer (CRC), the hyperactivation of Wnt/beta-catenin signaling by a mutation of both adenomatous polyposis coli (APC) and K Ras increases the size of the CSC population. We previously showed that CPD0857 inactivates Wnt/beta-catenin signaling by promoting the ubiquitin-dependent proteasomal degradation of beta-catenin and Ras proteins, thereby decreasing proliferation and increasing the apoptosis of CRC lines. CPD0857 also decreased the growth and invasiveness of CRC cells harboring mutant K Ras resistant to EGFR mAb therapy. Here, we show that CPD0857 treatment decreases proliferation and increases the neuronal differentiation of neural progenitor cells (NPCs). CDP0857 effectively reduced the expression of CSC markers and suppressed self-renewal capacity. CPD0857 treatment also inhibited the proliferation and expression of CSC markers in D K Ras MT cells carrying K Ras, APC and PI3K mutations, indicating the inhibition of PI3K/AKT signaling. Moreover, CPD0857-treated xenograft mice showed a regression of tumor growth and decreased numbers of CSCs in tumors. We conclude that CPD0857 could serve as the basis of a drug development strategy targeting CSCs activated through Wnt/beta-catenin-Ras MAPK-PI3K/AKT signaling in CRCs.

Automated summary

CPD0857 has been found to inhibit tumor stem cells in colorectal cancer, reducing proliferation and promoting differentiation, which may serve as a potential drug targeting CSCs.